Company & Sponsor Intelligence
Institute for Neurodegenerative Disorders
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting0
Completed3
Countries1
Therapeutic footprint
alzheimersparkinsons
Indexed studies
NCT00134784Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
parkinsons · PHASE2
parkinsons · PHASE2
NCT01028209Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
NCT01217021Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
alzheimers · United StatesEARLY_PHASE1
alzheimers · United StatesEARLY_PHASE1
NCT00870974A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
NCT00657813Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →